A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2015
At a glance
- Drugs BIIB 022 (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Biogen
- 29 Sep 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 29 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jul 2011 Planned End Date changed from 1 Nov 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.